{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:45:43Z","timestamp":1792478743526,"version":"4.5.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1089\/jop.2021.0090","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:49:47Z","timestamp":1770814187000},"page":"459-467","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Suprachoroidal Injection of Triamcinolone Acetonide Suspension: Ocular\n                  Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels\n                  in the Chorioretina"],"prefix":"10.1177","volume":"38","author":[{"given":"Leroy","family":"Muya","sequence":"first","affiliation":[{"name":"Clearside Biomedical, Inc., Alpharetta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viral","family":"Kansara","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Inc., Alpharetta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Cavet","sequence":"additional","affiliation":[{"name":"Bausch + Lomb, Rochester, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Inc., Alpharetta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/989501"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.10.006"},{"key":"e_1_3_4_4_2","author":"Sacconi R.","unstructured":"Sacconi R., , Giuffr\u00e8 C., , Corbelli E., , Borrelli E., ,\n                     Querques G., , and Bandello F. Emerging therapies in the management of macular\n                     edema: a review. F1000Res. 8:F1000 Faculty Rev-1413,\n                     2019.","journal-title":"F1000Res"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S40268"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01314-y"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.02.009"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2007.01578.x"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210801800318"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.101675"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2009.02033.x"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.11.050"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.12.001"},{"key":"e_1_3_4_14_2","first-page":"4925","article-title":"Pharmacokinetics and Ocular Tolerability of Suprachoroidal CLS-AX (axitinib injectable suspension) in rabbits","volume":"61","author":"Muya L.","year":"2020","unstructured":"Muya L., , Kansara V., , and Ciulla T. Pharmacokinetics and\n                     Ocular Tolerability of Suprachoroidal CLS-AX (axitinib injectable suspension)\n                     in rabbits. Invest. Ophthalmol. Vis. Sci. 61:4925,\n                     2020.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_15_2","first-page":"1","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"00","author":"Kansara V.","year":"2020","unstructured":"Kansara V., , Muya L., , Wan C., , and Ciulla T.A.\n                     Suprachoroidal delivery of viral and nonviral gene therapy for retinal\n                     diseases. J. Ocul. Pharmacol. Ther. 00:1\u20139, 2020.","journal-title":"J. Ocul. Pharmacol. Ther"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.7.19"},{"key":"e_1_3_4_17_2","first-page":"4112","article-title":"Targeted delivery of triamcinolone acetonide and CLS011A to the posterior ocular tissues via suprachoroidal administration","volume":"58","author":"Burke B.","year":"2017","unstructured":"Burke B., , Patel S.R., , Taraborelli D., , Struble C.B., ,\n                     and Noronha G. Targeted delivery of triamcinolone acetonide and CLS011A to the\n                     posterior ocular tissues via suprachoroidal administration. Invest. Ophthalmol.\n                     Vis. Sci. 58:4112, 2017.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020288"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.02.021"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.03.001"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14042"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-11747"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.006"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002279"},{"key":"e_1_3_4_25_2","author":"Henry C.R.","year":"2021","unstructured":"Henry C.R., , Shah M., , Barakat M.R., et al.\n                     Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial\n                     (AZALEA). Br. J. Ophthalmol. 2021 [Epub ahead of print];\n                     DOI:10.1136\/bjophthalmol-2020-318019.","journal-title":"Br. J. Ophthalmol"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.05.045"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0271-y"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9872"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116907"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-011-9625-y"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.1.24"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2005.00592.x"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273940500545684"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1867532"},{"key":"e_1_3_4_35_2","unstructured":"FDA. Inactive Ingredient Search for Approved Drug Products.\n                     www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm Accessed November10\n                     2021."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2004.07.007"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(03)00159-0"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02880-2"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.07.033"},{"key":"e_1_3_4_40_2","author":"Khurana R.N.","year":"2021","unstructured":"Khurana R.N., , Merrill P., , Yeh S., et al. Extension\n                     study of the safety and efficacy of CLS-TA for treatment of macular oedema\n                     associated with non-infectious uveitis (MAGNOLIA). Br. J. Ophthalmol. 2021\n                     [Epub ahead of print];\n                     DOI:10.1136\/bjophthalmol-2020-317560.","journal-title":"Br. J. Ophthalmol"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.024"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2021.0090","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:45:07Z","timestamp":1772469907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2021.0090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1089\/jop.2021.0090"],"URL":"https:\/\/doi.org\/10.1089\/jop.2021.0090","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]}}}